BioPharmX
Innovative drug-delivery products through its unique, patented platform technologies for pharmaceutical and otc.
| Date | Investors | Amount | Round |
|---|---|---|---|
| - | investor investor | €0.0 | round |
| N/A | €0.0 | round | |
| investor | €0.0 | round | |
| N/A | €0.0 | round | |
| N/A | €0.0 | round | |
| investor | €0.0 | round | |
* | $14.0m | Acquisition | |
| Total Funding | 000k | ||
| USD | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 |
|---|---|---|---|---|---|---|---|
| Revenues | 0000 | 0000 | 0000 | 0000 | 0000 | 0000 | 0000 |
| % growth | 185 % | 56 % | (27 %) | (5 %) | 110 % | (38 %) | 11 % |
| EBITDA | 0000 | 0000 | 0000 | 0000 | 0000 | 0000 | 0000 |
| Profit | 0000 | 0000 | 0000 | 0000 | 0000 | 0000 | 0000 |
| % profit margin | 72 % | 81 % | 81 % | 82 % | 83 % | 80 % | 81 % |
| EV | 0000 | 0000 | 0000 | 0000 | 0000 | 0000 | 0000 |
| EV / revenue | 00.0x | 00.0x | 00.0x | 00.0x | 00.0x | 00.0x | 00.0x |
| EV / EBITDA | 00.0x | 00.0x | 00.0x | 00.0x | 00.0x | 00.0x | 00.0x |
| R&D budget | 0000 | 0000 | 0000 | 0000 | 0000 | 0000 | 0000 |
Source: Company filings or news article
Related Content
Timber Pharmaceuticals focuses on advancing innovative clinical research to develop novel treatments for rare dermatologic diseases that currently have limited or no treatment options. The company operates within the medical dermatology market, targeting orphan indications—conditions affecting a small percentage of the population. Timber Pharmaceuticals primarily serves patients with unmet medical needs and collaborates with healthcare professionals and researchers to bring new therapies to market. The business model revolves around the development and commercialization of investigational therapies with proven mechanisms of action, supported by decades of clinical experience and robust safety profiles. Revenue is generated through the successful approval and sale of these therapies, as well as potential partnerships and licensing agreements.
Keywords: dermatology, rare diseases, clinical research, orphan indications, investigational therapies, medical dermatology, novel treatments, unmet needs, proven mechanisms, safety profiles.